An HLA-A2.1-transgenic rabbit model to study immunity to papillomavirus infection

Journal of Immunology

Volumn 177, Issue 11, 2006, Pages 8037-8045

  Hu, Jiafen ^a,b   Peng, Xuwen ^b   Schell, Todd D ^b   Budgeon, Lynn R ^a,b   Cladel, Nancy M ^a,b   Christensen, Neil D ^a,b  

^a PENN STATE CANCER INSTITUTE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EPITOPE; GLYCOPROTEIN E1; HLA A2 ANTIGEN; HLA A2.1 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN E7; UNCLASSIFIED DRUG; VIRUS DNA;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL SURFACE; CLONE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MALE; MUTANT; NONHUMAN; PAPILLOMA VIRUS; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; SPLEEN CELL; TRANSGENIC ANIMAL; VIRUS CELL INTERACTION; VIRUS IMMUNITY;

EID: 33751585380     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.11.8037     Document Type: Article

References (45)

1. Frazer, I. H. 2004. Prevention of cervical cancer through papillomavirus vaccination. Nat. Rev. Immunol. 4: 46-54.
2. Villa, L. L., R. L. Costa, C. A. Petta, R. P. Andrade, K. A. Ault, A. R. Giuliano, C. M. Wheeler, L. A. Koutsky, C. Malm, M. Lehtinen, et al. 2005. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6: 271-278.
3. Poland, G. A., R. M. Jacobson, L. A. Koutsky, G. M. Tamms, R. Railkar, J. F. Smith, J. T. Bryan, P. F. Cavanaugh, Jr., K. U. Jansen, and E. Barr. 2005. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial. Mayo Clin. Proc. 80: 601-610.
4. Evans, T. G., W. Bonnez, R. C. Rose, S. Koenig, L. Demeter, J. A. Suzich, D. O'Brien, M. Campbell, W. I. White, J. Balsley, and R. C. Reichman. 2001. A phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J. Infect. Dis. 183: 1485-1493.
5. Williamson, A. L., J. A. Passmore, and E. P. Rybicki. 2005. Strategies for the prevention of cervical cancer by human papillomavirus vaccination. Best Pract. Res. Clin. Obstet. Gynaecol. 19: 531-544.
6. Lowy, D. R., and J. T. Schiller. 2006. Prophylactic human papillomavirus vaccines. J. Clin. Invest. 116: 1167-1173.
7. Han, R., N. M. Cladel, C. A. Reed, X. Peng, and N. D. Christensen. 1999. Protection of rabbits from viral challenge by gene gun-based intracutaneous vaccination with a combination of cottontail rabbit papillomavirus E1, E2, E6, and E7 genes. J. Virol. 73: 7039-7043.
8. Christensen, N. D. 2005. Emerging human papillomavirus vaccines. Expert Opin. Emerg. Drugs 10: 5-19.
9. Moore, R. A., S. Walcott, K. L. White, D. M. Anderson, S. Jain, A. Lloyd, P. Topley, L. Thomsen, G. W. Gough, and M. A. Stanley. 2003. Therapeutic immunisation with COPV early genes by epithelial DNA delivery. Virology 314: 630-635.
10. Hallez, S., P. Simon, F. Maudoux, J. Doyen, J. C. Noel, A. Beliard, X. Capelle, F. Buxant, I. Fayt, A. C. Lagrost, et al. 2004. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol. Immunother. 53: 642-650.
11. Borysiewicz, L. K., A. Fiander, M. Nimako, S. Man, G. W. Wilkinson, D. Westmoreland, A. S. Evans, M. Adams, S. N. Stacey, M. E. Boursnell, et al. 1996. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347: 1523-1527.
12. van Driel, W. J., M. E. Ressing, G. G. Kenter, R. M. Brandt, E. J. Krul, A. B. van Rossum, E. Schuuring, R. Offringa, T. Bauknecht, A. Tamm-Hermelink, et al. 1999. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur. J. Cancer 35: 946-952.
13. Wlazlo, A. P., H. Deng, W. Giles-Davis, and H. C. Ertl. 2004. DNA vaccines against the human papillomavirus type 16 E6 or E7 oncoproteins. Cancer Gene Ther. 11: 457-464.
14. Fausch, S. C., D. M. Da Silva, G. L. Eiben, I. C. Le Poole, and W. M. Kast. 2003. HPV protein/peptide vaccines: from animal models to clinical trials. Front. Biosci. 8: s81-s91.
15. Campo, M. S. 2002. Animal models of papillomavirus pathogenesis. Virus Res. 89: 249-261.
16. Christensen, N. D. 2005. Cottontail rabbit papillomavirus (CRPV) model system to test antiviral and immunotherapeutic strategies. Antivir. Chem. Chemother. 16: 355-362.
17. Leachman, S. A., M. Shylankevich, M. D. Slade, D. Levine, R. K. Sundaram, W. Xiao, M. Bryan, D. Zelterman, R. E. Tiegelaar, and J. L. Brandsma. 2002. Ubiquitin-fused and/or multiple early genes from cottontail rabbit papillomavirus as DNA vaccines. J. Virol. 76: 7616-7624.
18. Hu, J., R. Han, N. M. Cladel, M. D. Pickel, and N. D. Christensen. 2002. Intracutaneous DNA vaccination with the E8 gene of cottontail rabbit papillomavirus induces protective immunity against virus challenge in rabbits. J. Virol. 76: 6453-6459.
19. Kreider, J. W., N. M. Cladel, S. D. Patrick, P. A. Welsh, S. L. DiAngelo, J. M. Bower, and N. D. Christensen. 1995. High efficiency induction of papillomas in vivo using recombinant cottontail rabbit papillomavirus DNA. J. Virol. Methods 55: 233-244.
20. Brandsma, J. L., and W. Xiao. 1993. Infectious virus replication in papillomas induced by molecularly cloned cottontail rabbit papillomavirus DNA. J. Virol. 67: 567-571.
21. Franchini, G., J. Tartaglia, P. Markham, J. Benson, J. Fullen, M. Wills, J. Arp, G. Dekaban, E. Paoletti, and R. C. Gallo. 1995. Highly attenuated HTLV type I-env poxvirus vaccines induce protection against a cell-associated HTLV type I challenge in rabbits. AIDS Res. Hum. Retroviruses 11: 307.
22. Romanowski, E. G., K. A. Yates, and Y. J. Gordon. 2002. Topical corticosteroids of limited potency promote adenovirus replication in the Ad5/NZW rabbit ocular model. Cornea 21: 289-291.
23. Hayashi, K., Z. Jin, S. Onoda, H. Joko, N. Teramoto, N. Ohara, W. Oda, T. Tanaka, Y. X. Liu, T. R. Koirala, et al. 2003. Rabbit model for human EBV-associated hemophagocytic syndrome (HPS): sequential autopsy analysis and characterization of IL-2-dependent cell lines established from herpesvirus papio-induced fatal rabbit lymphoproliferative diseases with HPS. Am. J. Pathol. 162: 1721-1736.
24. Dorman, S. E., C. L. Hatem, S. Tyagi, K. Aird, J. Lopez-Molina, M. L. Pitt, B. C. Zook, A. M. Dannenberg, Jr., W. R. Bishai, and Y. C. Manabe. 2004. Susceptibility to tuberculosis: clues from studies with inbred and outbred New Zealand White rabbits. Infect. Immun. 72: 1700-1705.
25. ras oncogene in epidermis. Am. J. Pathol. 155: 315-324.
26. Ressing, M. E., A. Sette, R. M. P. Brandt, J. Ruppert, P. A. Wentworth, M. Hartman, C. Oseroff, H. M. Grey, C. J. M. Melief, and W. M. Kast. 1995. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J. Immunol. 154: 5934-5943.
27. Schell, T. D., J. D. Lippolis, and S. S. Tevethia. 2001. Cytotoxic T lymphocytes from HLA-A2.1 transgenic mice define a potential human epitope from simian virus 40 large T antigen. Cancer Res. 61: 873-879.
28. Hu, J., X. Peng, N. M. Cladel, M. D. Pickel, and N. D. Christensen. 2005. Large cutaneous rabbit papillomas that persist during cyclosporin A treatment can regress spontaneously after cessation of immunosuppression. J. Gen. Virol. 86: 55-63.
29. Kierstead, T. D., and M. J. Tevethia. 1993. Association of p53 binding and immortalization of primary C57BL/6 mouse embryo fibroblasts by using simian virus 40 T-antigen mutants bearing internal overlapping deletion mutations. J. Virol. 67: 1817-1829.
30. Embers, M. E., L. R. Budgeon, M. Pickel, and N. D. Christensen. 2002. Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of 12, the minor capsid protein. J. Virol. 76: 9798-9805.
31. Donnes, P., and A. Elofsson. 2002. Prediction of MHC class I binding peptides, using SVMHC. BMC Bioinformatics 3: 25.
32. Velders, M. P., S. Weijzen, G. L. Eiben, A. G. Elmishad, P. M. Kloetzel, T. Higgins, R. B. Ciccarelli, M. Evans, S. Man, L. Smith, and W. M. Kast. 2001. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J. Immunol. 166: 5366-5373.
33. Hu, J., N. M. Cladel, Z. Wang, R. Han, M. D. Pickel, and N. D. Christensen. 2004. GM-CSF enhances protective immunity to cottontail rabbit papillomavirus E8 genetic vaccination in rabbits. Vaccine 22: 1124-1130.
34. Christensen, N. D., R. Han, and J. W. Kreider. 2000. Cottontail rabbit papillomavirus (CRPV). In Persistent Viral Infections. R. Ahmed and I. Chen, eds. John Wiley & Sons, Sussex, pp. 485-502.
35. Hu, J., N. M. Cladel, M. D. Pickel, and N. D. Christensen. 2002. Amino acid residues in the carboxy-terminal region of cottontail rabbit papillomavirus e6 influence spontaneous regression of cutaneous papillomas. J. Virol. 76: 11801-11808.
36. Salmon, J., M. Nonnenmacher, S. Caze, P. Flamant, O. Croissant, G. Orth, and F. Breitburd. 2000. Variation in the nucleotide sequence of cottontail rabbit papillomavirus a and b subtypes affects wart regression and malignant transformation and level of viral replication in domestic rabbits. J. Virol. 74: 10766-10777.
37. + T-cell peptide epitope of vaccinia and variola viruses. J. Virol. 78: 7052-7060.
38. Loirat, D., F. A. Lemonnier, and M. L. Michel. 2000. Multiepitopic HLA-A*0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization. J. Immunol. 165: 4748-4755.
39. + cytotoxic T-cell epitopes. J. Virol. 73: 5320-5325.
40. Kulaga, H., T. M. Folks, R. Rutledge, and T. J. Kindt. 1988. Infection of rabbit T-cell and macrophage lines with human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 85: 4455-4459.
41. Speck, R. F., M. L. Penn, J. Wimmer, U. Esser, B. F. Hague, T. J. Kindt, R. E. Atchison, and M. A. Goldsmith. 1998. Rabbit cells expressing human CD4 and human CCR5 are highly permissive for human immunodeficiency virus type 1 infection. J. Virol. 72: 5728-5734.
42. Schell, K., and J. Maryak. 1966. Susceptibility of rabbit kidney cells of various passage levels to infection with SV-40 virus. Arch. Gesamte Virusforsch. 19: 403-414.
43. Cody, V., H. Shen, M. Shlyankevich, R. E. Tigelaar, J. L. Brandsma, and D. J. Hanlon. 2005. Generation of dendritic cells from rabbit bone marrow mononuclear cell cultures supplemented with hGM-CSF and hIL-4. Vet. Immunol. Immunopathol. 103: 163-172.
44. Taylor, J. M. 1997. Transgenic rabbit models for the study of atherosclerosis. Ann. NY Acad. Sci. 811: 146-154.
45. Fan, J., and T. Watanabe. 2003. Transgenic rabbits as therapeutic protein bioreactors and human disease models. Pharmacol. Ther. 99: 261-282.